Skip to main content

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Terminated · Phase 3 · NCT05028569

Conditions: Episodic Migraine

At a glance

Research payments reported, 2025
$158,041
U.S. investigators named
26
Sites paid
25
Planned or actual enrollment
775

About the trial

Sponsor
AbbVie
Tested
BOTOX (drug), Placebo (drug)
Dates
Started 2021-11-05; completion 2024-11-06
Results posted
Yes

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. BOTOX is being developed for the prevention of migraine in adults with episodic migraine (EM). Participants will be enrolled in 3 different treatment groups. There is 1 in 3 chance that participants will be assigned to receive placebo. Approximately 777 adult …

From ClinicalTrials.gov, last updated 2025-12-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $158,041 in research payments for this study in 2025 (53 payments).

Products named: Botox

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Minneapolis Clinic of Neurology LTD $17,540
  • Texas Neurology PA $12,748
  • Coastal Carolina Research Cntr LLC $11,034
  • Conquest Research LLC $10,972
  • Sensible Healthcare LLC $10,940
  • Wr-Pri LLC $10,771
  • University of South Florida $10,740
  • Fieve Clinical Research Inc $10,250
  • Clinical Trials of South Carolina $8,600
  • Clinvest Headlands LLC $8,100
  • Jefferson Medical College at Thomas Jefferson University $7,502
  • Hope Clinical Research Inc $7,185
  • Sentara Leigh Hospital, VA $5,730
  • Albuquerque Clinical Trials Inc $5,055
  • Lehigh Center for Clinical Research $3,887
  • Alice Castilone DBA Upstate Clinical Research Associates LLC $3,575
  • Neuro-Pain Medical Center Inc $3,389
  • Charlottesville Medical Research Center LLC $3,060
  • Boston Clinical Trials LLC $2,675
  • Accellacare US Inc $2,500
  • Sun Valley Research Center Inc $1,067
  • Velocity Clinical Research Inc $399
  • Colorado Springs Neurological Associates $175
  • Kansas Institute of Research $98
  • Advanced Neurosciences Research LLC $50

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.